Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-label Trial of Intravenous CAVATAK^TM in Combination With Pembrolizumab for the Treatment of Patients With Advanced NSCLC

NCT02824965 is registered in ClinicalTrials.gov with Olivia Newton-John Cancer Research Institute as lead sponsor.

NCT NCT02824965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02824965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-label Trial of Intravenous CAVATAK^TM in Combination With Pembrolizumab for the Treatment of Patients With Advanced NSCLC
Lead sponsor
Olivia Newton-John Cancer Research Institute
Phase
Phase 1
Overall status
Unknown status
Start date
August 9, 2017
Completion date
October 31, 2021
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer